Kevin Tschetter, MD
Internal Medicine · Draper, UTNPI 1912922923
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by AbbVie at 46.7% of the total. Reporting peaked in 2019 at $5,042 and has fallen 96.3% since, to $189 in 2025. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $32.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Biohaven Pharmaceuticals, Inc.$1K
- Biogen$450
- Abbott$294
- Novo Nordisk$293
- Amgen$262
- plus $2K from 23 others
What the payments were for
- Consulting fees$4,51756%
- Speaking & faculty fees$190%
- Food & beverage$3,46943%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $3,745 |
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| Biogen | 3 | $450 |
| Abbott | 17 | $294 |
| Novo Nordisk | 35 | $293 |
| Amgen | 16 | $262 |
| Pfizer | 23 | $245 |
| Boehringer Ingelheim | 14 | $234 |
| GSK | 16 | $209 |
| Johnson & Johnson | 11 | $177 |
| Sanofi-aventis U.S. LLC | 11 | $165 |
| AstraZeneca | 12 | $148 |
| E.r. Squibb & Sons, L.L.C. | 8 | $121 |
| Boston Scientific | 3 | $59 |
| Antares Pharma, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 3 | $49 |
| BD | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $32 |
| Novartis | 2 | $30 |
| Medtronic(2 entities) | 2 | $29 |
| Lilly USA, LLC | 2 | $29 |
| Merck | 2 | $26 |
| GE HealthCare | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| MDD US Operations, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- TYSABRI$450
How this compares
$8,016 in reported general payments places this provider in the 90th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 203 | $163,480 |
| OzempicSemaglutide | 123 | $140,008 |
| TrulicityDulaglutide | 72 | $98,865 |
| JardianceEmpagliflozin | 94 | $92,786 |
| MounjaroTirzepatide | 53 | $67,207 |
| XareltoRivaroxaban | 49 | $64,820 |
| MyrbetriqMirabegron | 86 | $61,322 |
| LinzessLinaclotide | 32 | $33,532 |
| GlyxambiEmpagliflozin/Linagliptin | 20 | $24,384 |
| RybelsusSemaglutide | 14 | $21,869 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $21,195 |
| FarxigaDapagliflozin Propanediol | 19 | $19,506 |
| RytaryCarbidopa/Levodopa | 25 | $19,489 |
| Bydureon BciseExenatide Microspheres | 15 | $19,413 |
| TradjentaLinagliptin | 19 | $16,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $29 | $166,072125 claims |
| PfizerEliquis | $245 | $163,480203 claims |
| Novo NordiskOzempic, Rybelsus | $293 | $161,877137 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Spiriva Respimat | $234 | $145,624155 claims |
| Johnson & JohnsonXarelto | $177 | $64,82049 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $61,32286 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $148 | $46,31972 claims |
| AbbVieLinzess | $3,745 | $33,53232 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $165 | $15,45725 claims |
| GSKBreo Ellipta | $209 | $12,11028 claims |
| MerckBelsomra | $26 | $9,14514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Draper
- Philip RobertsDraper$5K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
- Barbara RizzardiSandy$30K
- Gerald GleichSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.